Research Paper Volume 13, Issue 7 pp 9627—9645
Hsa_circ_0053063 inhibits breast cancer cell proliferation via hsa_circ_0053063/hsa-miR-330-3p/PDCD4 axis
- 1 Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China
- 2 Tongji University School of Medicine, Shanghai 200092, China
- 3 Nanjing Medical University, Nanjing 211166, China
- 4 Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong, China
Received: June 24, 2020 Accepted: February 13, 2021 Published: March 19, 2021https://doi.org/10.18632/aging.202707
How to Cite
Copyright: © 2021 Ji et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Breast cancer (BC) is one of the most common malignancies and its mortality is the highest among females. Circular RNAs (circRNAs), a novel group of non-coding RNAs, play an important regulatory role in angiogenesis and cancer progression. Hsa_circ_0053063 is a circRNA generated from several exons of HADHA. The potential role of hsa_circ_0053063 in BC remains unknown and needs to be explored. Hsa_circ_0053063 was mainly located in the cytoplasm and activated in BC tissues and cell lines. The binding position between hsa_circ_0053063 and miR-330-3p was confirmed by luciferase reporter assay. Moreover, hsa_circ_0053063 inhibited cell viability, proliferation, and progression of BC through the negative regulation of miR-330-3p. Programmed cell death 4 (PDCD4) is a direct target of miR-330-3p. Besides, the over-expression of miR-330-3p promoted cell progression by directly targeting and regulating PDCD4. Mechanistically, hsa_circ_0053063 activated PDCD4 by targeting miR-330-3p to inhibit BC progression. In conclusion, hsa_circ_0053063 inhibits breast cancer cell proliferation via hsa_circ_0053063/hsa-miR-330-3p/PDCD4 axis, which may provide a new therapeutic target for BC patients.
circRNA: Circular RNA; ncRNA: Non-coding RNA; GEO: Gene Expression Omnibus; PDCD4: Programmed Cell Death 4; GAPDH: Glyceraldehyde-3-Phosphate Dehydrogenase; qRT-PCR: Quantitative real-time polymerase chain reaction; ceRNA: competing endogenous RNAs; HADHA: hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha.